Drug Profile
Pneumococcal polysaccharide vaccine 23-valent - Tianjin CanSino Biotechnology
Alternative Names: PPV - Tianjin CanSino BiotechnologyLatest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pneumococcal infections
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Pneumococcal infections (Prevention) in China (unspecified route) (Tianjin CanSino Biotechnology pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Pneumococcal-infections(Prevention) in China
- 18 Jul 2016 Preclinical trials in Pneumococcal infections (Prevention) in China (unspecified route)